Amino-PEG4-Boc

CAS No. 581065-95-4

Amino-PEG4-Boc ( —— )

Catalog No. M24572 CAS No. 581065-95-4

Amino-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 26 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Amino-PEG4-Boc
  • Note
    Research use only, not for human use.
  • Brief Description
    Amino-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • Description
    Amino-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
  • Synonyms
    ——
  • Pathway
    PROTACs
  • Target
    PROTAC
  • Recptor
    PEGs;Alkyl/ether
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    581065-95-4
  • Formula Weight
    321.4
  • Molecular Formula
    C15H31NO6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(OC(C)(C)C)CCOCCOCCOCCOCCN
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
molnova catalog
related products
  • MZ 1

    MZ 1 is a PROTAC BRD4 degrader. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. Kds of 382/120, 119/115, and 307/228 nM for BRD4 BD1/2, BRD3 BD1/2, and BRD2 BD1/2, respectively.

  • Foretinib-Based PROT...

    Foretinib-Based PROTAC 7 is a VHL-recruiting PROTAC that induces the degradation of c-Met in a dose- and time-dependent fashion in MDA-MB-231 cells.

  • Amino-PEG11-amine

    Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.